Nina S. Kjellson Sells 4,825 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 4,825 shares of the company’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $16.26, for a total value of $78,454.50. Following the completion of the sale, the director now owns 3,702,595 shares of the company’s stock, valued at approximately $60,204,194.70. The trade was a 0.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Tyra Biosciences Trading Down 0.7 %

Shares of Tyra Biosciences stock opened at $15.39 on Wednesday. The stock has a 50 day moving average of $15.37 and a 200 day moving average of $19.09. Tyra Biosciences, Inc. has a 12 month low of $12.48 and a 12 month high of $29.60. The firm has a market cap of $778.73 million, a PE ratio of -9.56 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

Institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at approximately $149,000. Franklin Resources Inc. bought a new stake in shares of Tyra Biosciences in the 3rd quarter valued at approximately $278,000. Valence8 US LP bought a new stake in shares of Tyra Biosciences in the 3rd quarter valued at approximately $310,000. SG Americas Securities LLC bought a new stake in shares of Tyra Biosciences during the 3rd quarter worth approximately $311,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Tyra Biosciences during the 3rd quarter worth approximately $333,000. 84.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TYRA has been the subject of a number of analyst reports. UBS Group initiated coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Monday, January 13th. Wedbush reiterated an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. Finally, Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $30.50.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.